Clinical Trial Update: ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial in cervical cancer comparing three-weekly carboplatin/paclitaxel with or without the angiogenesis inhibitor nintedanib; the study status is comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nintedanib (nintedanib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Belgian Gynaecological Oncology Group | Conditions: Uterine Cervical Neoplasms | Phase 2 | Status: COMPLETED